GlassScriptPhysician profile
Melissa Galloway
NPI 1245018878
$2,718.07
in general payments reported to CMS, 2019-2025
28 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $262 · 2024: $1,967 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,718.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $315.54 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $295.85 | 2023-2025 | |
| Exact Sciences Corporation | $206.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $178.72 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $172.76 | 2023-2024 | |
| Ardelyx, INC. | $161.83 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $151.10 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Corcept Therapeutics | $119.14 | 2024-2025 | Korlym |
| Novo Nordisk INC | $113.45 | 2023-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $112.03 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $104.31 | 2024-2025 | Gemtesa |
| Esperion Therapeutics, INC. | $91.46 | 2024 | Nexletol |
| Dexcom, INC. | $73.78 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $73.32 | 2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $69.01 | 2023 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.79 | 2024 | Jardiance |
| Shield Therapeutics INC | $57.87 | 2024 | |
| Merck Sharp & Dohme LLC | $56.93 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Phathom Pharmaceuticals, INC. | $51.05 | 2024 | Voquezna |
| Lundbeck LLC | $44.00 | 2024-2025 | Rexulti |
| Amgen INC. | $37.80 | 2024 | Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $37.70 | 2023-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $36.87 | 2024 | |
| Eisai INC. | $25.03 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $18.19 | 2025 | Zoryve |
| Tactile Systems Technology INC | $17.74 | 2025 | Nimbl, Flexitouch Plus |
| Alexion Pharmaceuticals, INC. | $17.49 | 2024 | Strensiq |
| Vertos Medical, INC. | $16.83 | 2024 | Mild Device Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Galloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.